N/A N=30

Tolerance to Residual Astigmatism in Eyes With Vivity®

Lenses, Intraocular

Bottom Line

View on ClinicalTrials.gov: NCT05392998 ↗

Enrolled (actual)

Serious AEs

0.0%

Results posted

Mar 2024

Primary outcome: Primary: Distance Against the Rule Astimatism — 0.01 LogMAR

Study Design & Population

Study type: Observational
Phase: N/A
Interventions: Cataract surgery with Vivity intraocular lens implantation (Device)
Age: Adult, Older Adult · 40+ yrs
Sex: All
Sponsor: Clínica Rementería
Primary completion: Mar 2022

Outcome Measures

Outcome	Result	p-value
PRIMARY Distance Against the Rule Astimatism	0.01	—
PRIMARY Distance Oblique Astigmatism	0.01	—
PRIMARY Distance With the Rule Astigmatism	0.01	—

Summary

Low amounts of postoperative residual astigmatism may worsen the visual performance of patients implanted with presbyopia- correcting intraocular lenses (IOLs). Although extended depth of focus (EDoF) IOLS have introduced optical improvements, it is important to determine the tolerance of these IOLs to postoperative astigmatism. This is important for an appropriate surgical planning. Therefore, the aim of this study is to simulate and assess the impact of mild amounts of residual mixed astigmatisms with the axis oriented in different positions (vertical, oblique and horizontal) in eyes implanted with the Vivity® IOL.

Eligibility Criteria

Inclusion Criteria

Patients >40 years old that undergo routine cataract surgery
Bilateral implantation of Vivity ® IOL

Exclusion Criteria

Corneal astigmatism ≥1.0 diopters (D )
Amblyopia
Previous ocular surgery
Presence of ocular pathologies
Abnormal iris
Patients with intra- or postoperative complications
Postoperative best distance corrected visual acuity (BDCVA) 0.50D

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT05392998). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.